(VIANEWS) – ELIS (ELIS.PA), NORSKE SKOG (NSKOG.OL), INPOST (INPST.AS) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. ELIS (ELIS.PA)
77.2% sales growth and 7.22% return on equity
Elis SA provides flat linen, workwear, and hygiene and well-being solutions in France, Central Europe, Scandinavia, Eastern Europe, the United Kingdom, Ireland, Latin America, Southern Europe, and internationally. The company offers table, bed, kitchen, patient, and bath linens; workwear and personal protective equipment; beverage solutions, such as water coolers and accessories, cups and bottles, and coffee machines; floor protection mats and mops; industrial wipers; and pest and rodent control, insect control, or disinfection services. It provides washroom hygiene services, such as hand washing and drying, toilet hygiene and urinals, lavatories, and air fragrancing; and reusable cleanroom garments, footwear, goggles, and related contamination control solutions, as well as cleaning systems. In addition, the company offers various solutions for collection and disposal of infectious waste, as well as laundry facilities. It serves the catering, accommodation, healthcare and social welfare, industries, trade and retail, and services sectors, as well as public authorities and administration. The company was founded in 1883 and is headquartered in Saint-Cloud, France.
Earnings Per Share
As for profitability, ELIS has a trailing twelve months EPS of €1.06.
PE Ratio
ELIS has a trailing twelve months price to earnings ratio of 19.87. Meaning, the purchaser of the share is investing €19.87 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.22%.
Moving Average
ELIS’s worth is below its 50-day moving average of €21.30 and above its 200-day moving average of €20.12.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on May 27, 2024, the estimated forward annual dividend rate is 0.43 and the estimated forward annual dividend yield is 2.11%.
Yearly Top and Bottom Value
ELIS’s stock is valued at €21.06 at 17:20 EST, way under its 52-week high of €23.58 and way higher than its 52-week low of €14.96.
More news about ELIS.
2. NORSKE SKOG (NSKOG.OL)
32.1% sales growth and 8.63% return on equity
Norske Skog ASA engages in the production and sale of publication and packaging paper products in Norway, rest of Europe, North America, Australasia, Asia, and Africa. It operates in Publication paper Europe, Publication paper Australasia, and Packaging paper segments. The company offers newsprint paper products comprising standard newsprint and other papers; magazine papers, including super calendared and lightweight coated papers; and recycled containerboards. Its products are primarily used in newspapers and magazines, periodicals, catalogues, brochures, advertising materials, inserts/flyers, supplements, free-sheets, directories, direct mail, and books. Norske Skog ASA was founded in 1962 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, NORSKE SKOG has a trailing twelve months EPS of kr5.27.
PE Ratio
NORSKE SKOG has a trailing twelve months price to earnings ratio of 7.17. Meaning, the purchaser of the share is investing kr7.17 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.63%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 12.6%, now sitting on 10.77B for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is a negative 123% and a negative 109.9%, respectively.
Sales Growth
NORSKE SKOG’s sales growth for the next quarter is 32.1%.
More news about NORSKE SKOG.
3. INPOST (INPST.AS)
21.7% sales growth and 72.91% return on equity
InPost S.A., together with its subsidiaries, operates as an out-of-home e-commerce enablement platform providing parcel locker services in Europe. It operates through four segments: APM (Automated Parcel Machines), To-Door, Mondial Relay, and International Other. The APM segment focuses on the delivery of parcels to APM. The To-Door segment delivers parcels using door-to-door couriers. The Mondial Relay segment delivers parcels to APM; and operates pick-up drop-off (PUDO) points in France, Spain, Belgium, the Netherlands, Luxembourg, and Portugal. The International Other segment delivers parcels to APM and PUDO points in the United Kingdom and Italy. The company also provides fulfilment services; marketing and IT services; InPost Pay services; and platform for fast-moving consumer goods products through InPost Fresh app. InPost S.A. was founded in 1999 and is headquartered in Luxembourg, Luxembourg.
Earnings Per Share
As for profitability, INPOST has a trailing twelve months EPS of €0.37.
PE Ratio
INPOST has a trailing twelve months price to earnings ratio of 41.08. Meaning, the purchaser of the share is investing €41.08 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 72.91%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 21.7%, now sitting on 9.27B for the twelve trailing months.
Sales Growth
INPOST’s sales growth is 21% for the present quarter and 21.7% for the next.
Yearly Top and Bottom Value
INPOST’s stock is valued at €15.20 at 17:20 EST, way under its 52-week high of €17.58 and way above its 52-week low of €8.71.
More news about INPOST.
4. SANOFI (SAN.PA)
7.4% sales growth and 5.82% return on equity
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, SANOFI has a trailing twelve months EPS of €4.3.
PE Ratio
SANOFI has a trailing twelve months price to earnings ratio of 21.15. Meaning, the purchaser of the share is investing €21.15 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.82%.
More news about SANOFI.
5. SATS (SATS.OL)
6.5% sales growth and 24.17% return on equity
Sats ASA provides fitness and training services in Norway, Sweden, Denmark, and Finland. It offers sportswear, fitness gear, bars, and energy drinks. The company operates fitness clubs under the SATS, ELIXIA, Fresh Fitness, and SATSYoga brand names. Sats ASA was founded in 1995 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, SATS has a trailing twelve months EPS of kr1.16.
PE Ratio
SATS has a trailing twelve months price to earnings ratio of 14.4. Meaning, the purchaser of the share is investing kr14.4 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.17%.
Moving Average
SATS’s worth is below its 50-day moving average of kr16.77 and higher than its 200-day moving average of kr16.42.
Revenue Growth
Year-on-year quarterly revenue growth grew by 7.7%, now sitting on 4.83B for the twelve trailing months.
Yearly Top and Bottom Value
SATS’s stock is valued at kr16.70 at 17:20 EST, way below its 52-week high of kr19.70 and way higher than its 52-week low of kr10.16.
Volume
Today’s last reported volume for SATS is 37839 which is 77.69% below its average volume of 169609.
More news about SATS.
